CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T c...

Full description

Bibliographic Details
Main Authors: Xiaomin Zhang, Lingling Zhu, Hui Zhang, Shanshan Chen, Yang Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
CAR-T cell
hematological malignancies
CAR-T related toxicities
antigen escape
immunosuppressive tumor microenvironment
combinatorial therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.927153/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.927153/full

Similar Items